Click Targets ‘Best-In-Class Digital Therapy For Chronic Weight Management’ With Better Therapeutics Acquisition
Firm Says Its Digital Therapeutic Will Combine With GLP-1s For Optimal Obesity Treatment
Executive Summary
Click will fold Better Therapeutics’ FDA-cleared AspyreRx prescription digital therapeutic into R&D for its own CT-181, which promises to optimize obesity treatment in combination with drugs such as GLP-1s and provide "valuable real-world data insights for providers and payers." Better Therapeutics shuttered its operations in March, signaling continued challenges for digital medicine innovators.